文献速递妇科

靶向骨桥蛋白通过抑制RhoA/ROS轴减轻子宫内膜异位症及炎症并经月经血实现无创体外检测

Targeting osteopontin alleviates endometriosis and inflammation by inhibiting the RhoA/ROS axis and achieves non-invasive in vitro detection via menstrual blood.
PubMed 文献 · Hum Reprod · 2024-01-01

研究纳入20例经腹腔镜和组织学确诊的子宫内膜异位症患者及10例无子宫内膜异位症对照,分离异位子宫内膜基质细胞与月经血子宫内膜细胞进行体外培养。体外实验显示异位子宫内膜基质细胞中骨桥蛋白(OPN)显著上调,敲低OPN可抑制坏死性凋亡及炎症因子释放;体内靶向OPN可抑制病灶生长;月经血中OPN亦显著上调,提示其作为无创检测指标的潜力。

要点

  • 异位子宫内膜基质细胞中骨桥蛋白(OPN)显著上调,敲低OPN可抑制坏死性凋亡及炎症因子释放。
  • OPN通过介导RhoA依赖性活性氧(ROS)产生并阻断混合谱系激酶结构域样蛋白在细胞膜磷酸化发挥作用。
  • 体内靶向OPN可抑制子宫内膜异位症病灶生长,月经血中OPN显著上调,提示无创检测可能。

核心结论

  • 靶向OPN通过抑制RhoA/ROS轴调控坏死性凋亡和炎症状态,从而减轻子宫内膜异位症,并实现月经血体外无创检测。

研究设计与样本

  • 研究纳入20例经腹腔镜和组织学确诊的子宫内膜异位症患者及10例无子宫内膜异位症对照,分离异位子宫内膜基质细胞和月经血子宫内膜细胞进行体外培养及后续实验。

主要发现

  • 体外实验显示异位子宫内膜基质细胞中OPN显著上调,敲低OPN可有效抑制坏死性凋亡及炎症因子释放。
  • OPN通过介导RhoA依赖性ROS产生并阻断混合谱系激酶结构域样蛋白在细胞膜磷酸化,从而抑制坏死性凋亡和炎症因子释放。
  • 体内靶向OPN可抑制子宫内膜异位症病灶生长。
  • 临床上子宫内膜异位症患者月经血中OPN亦显著上调。

临床怎么用

  • 作者认为靶向OPN为子宫内膜异位症的治疗和检测提供了可能性。

局限性

  • 由于手术标本获取的限制,研究主要收集月经周期增殖期和分泌期的子宫内膜异位症组织。
  • 所研究样本中观察到OPN显著过表达,但月经间期子宫内膜异位症组织中OPN的表达情况仍未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How does osteopontin (OPN) in endometriosis ectopic stromal cells (EESCs) participate in the pathogenesis of endometriosis and achieve non-invasive detection in vitro? SUMMARY ANSWER: Targeted OPN regulates endometriosis's necroptosis and inflammatory state by inhibiting the RhoA/reactive oxygen species (ROS) axis, thereby alleviating endometriosis and enabling non-invasive detection of menstrual blood in vitro. WHAT IS KNOWN ALREADY: Endometriosis is a chronic inflammatory disease. Recent studies have shown that OPN plays an important role in disease progression by regulating cell death and inflammation. STUDY DESIGN, SIZE, DURATION: The study included 20 patients diagnosed with endometriosis (confirmed by laparoscopy and histology) and 10 controls without endometriosis. Endometriotic stromal cells were isolated from endometrial samples, while menstrual blood endometrial cells (MESCs) were isolated from menstrual blood. These cells were then cultured in vitro and utilized in subsequent experiments. PARTICIPANTS/MATERIALS, SETTING, METHODS: OPN expression in EESCs was assessed using inflammatory factor sequencing, immunohistochemical staining (IHC), quantitative real-time PCR (qRT-PCR) analysis, and Western blotting (WB). The biological behavior of OPN and its effects on inflammatory factors were examined using EdU, wound-healing, Transwell, and ELISA assays. Necroptosis in EESCs and its impact on inflammatory factors were detected through qRT-PCR, WB, and Calcein-AM/PI fluorescence assays. The examination of mitochondrial stress in EESCs involved the use of the Mitochondrial Membrane Potential (ΔΨm) Assay, ROS detection, and Calcein-AM Loading/cobalt chloride Quenching. qRT-PCR, WB, and other experiments were conducted to verify the regulation of necroptosis and inflammatory factor levels in EESCs by OPN through the RhoA/ROS axis. Knockdown of OPN and its inhibitory effect on endometriosis lesion size were confirmed using AAV9 virus, IHC, qRT-PCR, WB, and other experiments. Additionally, OPN expression in MESCs was detected using transcriptome sequencing, RT-PCR, WB, and other experiments. MAIN RESULTS AND THE ROLE OF CHANCE: In vitro assays demonstrated a significant upregulation of OPN in EESCs, and the knockdown of OPN effectively inhibited necroptosis and the release of inflammatory factors. OPN inhibited necroptosis and inflammatory factor release by mediating RhoA-dependent ROS production and blocking mixed lineage kinase domain-like protein phosphorylation at the cell membrane. In vivo, targeting of OPN can inhibit the growth of endometriosis lesions. Clinically, OPN was also significantly upregulated in the menstrual blood of patients with endometriosis. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Due to limitations in obtaining surgical specimens, our study primarily involved collecting endometriosis tissues from women during the proliferative and secretory phases of the menstrual cycle. We observed a significant overexpression of OPN in the samples used for our investigation. However, the expression of OPN in endometriosis tissues during the intermenstrual phase remains unknown. WIDER IMPLICATIONS OF THE FINDINGS: Our findings highlight the pivotal role of the OPN/RhoA/ROS axis in the regulation of necroptosis and the release of inflammatory factors. OPN knockdown exerts a therapeutic effect in vivo, and the high expression detection of OPN in menstrual blood in vitro. In summary, targeting OPN provides possibilities for the treatment and detection of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Natural Science Foundation of China (82071626), the Zhejiang Province Public Welfare Technology Application Research Project (LGF21H040010), and the Clinical Research project of the Second Affiliated Hospital of Wenzhou Medical University (1010293). The authors have no conflicts of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Wang H, Wang B, Wu M, et al. Targeting osteopontin alleviates endometriosis and inflammation by inhibiting the RhoA/ROS axis and achieves non-invasive in vitro detection via menstrual blood. Hum Reprod. 2024. PMID: 38511216. doi:10.1093/humrep/deae052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。